TScan Therapeutics Reports Positive Phase 1 Data for TSC-101, Advancing to Phase 3
TCRX is trading near its 52-week low of $0.848 (9.8% above the low).
Summary
TScan Therapeutics announced positive initial data from its Phase 1 ALLOHA study for TSC-101, demonstrating strong efficacy and safety, and confirming its readiness to proceed to a pivotal Phase 3 trial.
Key Events · Product Development and Regulatory · TCRX
-
Positive Phase 1 Data
Initial data from Cohort C of the ALLOHA Phase 1 study for TSC-101 showed 11 of 14 patients achieved complete donor chimerism within approximately three weeks, with a 90% manufacturing success rate.
-
Favorable Safety Profile
TSC-101 infusions were generally well-tolerated, with safety consistent with previous cohorts and post-HCT adverse events.
-
Advancement to Phase 3
The positive data supports the company's plan to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study for TSC-101 this month.
-
KOL Event Scheduled
The company will host a virtual Key Opinion Leader (KOL) event today, June 22, 2026, to discuss the data and Phase 3 plans.
Analysis · TCRX · Life Sciences
This 8-K formally discloses positive initial data from Cohort C of the Phase 1 ALLOHA study for TSC-101, a T-cell therapy for heme malignancies. The data shows a high manufacturing success rate, strong rates of complete donor chimerism (an early indicator of efficacy), and a favorable safety profile. This clinical progress is critical for TScan Therapeutics, a clinical-stage micro-cap company, as it de-risks the program and supports the planned initiation of a pivotal Phase 3 study this month.
At the time of this filing, TCRX was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.1M. The 52-week trading range was $0.85 to $2.57. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.